A Single-center, Multi-arm, Open-label, Randomized, 3-period, Crossover, Phase 1 Study to Evaluate the DDI, PK, Safety, and Tolerability of Single Doses of SPR741 Co-administered With Three Different Antibiotics in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 08 Jan 2018
At a glance
- Drugs SPR 741 (Primary) ; Aztreonam; Ceftazidime; Tazobactam
- Indications Gram-negative infections
- Focus Pharmacokinetics
- Sponsors Spero Therapeutics
- 03 Jan 2018 Status changed from recruiting to completed.
- 20 Dec 2017 New trial record
- 14 Dec 2017 According to a Spero Therapeutics media release, company plans to annouce a top-line data from this trial in the first half of 2018.